UBS Group’s Ligand Pharmaceuticals LGND Stock Holding History

UBS Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,427	Closed	-$1.18M	–	9830
2021 Q2	$1.18M	Sell	14,427 -11,221	-44%	-$933K	﹤0.01%	4037
2021 Q1	$2.44M	Buy	+25,648	New	+$2.42M	﹤0.01%	3358
2020 Q4	–	Sell	-8,336	Closed	-$496K	–	8581
2020 Q3	$496K	Buy	+8,336	New	+$569K	﹤0.01%	4213
2020 Q2	–	Sell	-16,832	Closed	-$764K	–	8170
2020 Q1	$764K	Sell	16,832 -79,348	-82%	-$4.5M	﹤0.01%	3579
2019 Q4	$6.26M	Buy	96,180 +69,730	+264%	+$4.66M	﹤0.01%	2398
2019 Q3	$1.64M	Buy	+26,450	New	+$1.66M	﹤0.01%	3499
2015 Q1	–	Sell	-321	Closed	-$11K	–	9089
2014 Q4	$11K	Buy	+321	New	+$10.4K	﹤0.01%	8311

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

UBS Group's LGND Position: Q1 2026 in Review

UBS Group reduced its Ligand Pharmaceuticals (LGND) stake by 27% in Q1 2026, selling an estimated $7.61M and leaving 104,580 shares worth $20.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

UBS Group first reported a position in LGND in Q4 2014 and has held it in 46 quarters since. The position peaked at $27M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

UBS Group held 104,580 shares of Ligand Pharmaceuticals worth $20.9M as of Q1 2026.
UBS Group sold 38,487 Ligand Pharmaceuticals shares in Q1 2026, an estimated $7.61M.
Ligand Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2530 holding.
UBS Group first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
UBS Group's Ligand Pharmaceuticals position peaked at $27M in Q4 2025.
357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.